✦ LIBER ✦

Treatment of chronic hepatitis D: New advances, old challenges

✍ Scribed by Patrizia Farci

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 113 KB
Volume: 44
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21351

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advances in the treatment of chronic hep

Advances in the treatment of chronic hepatitis B virus infection

✍ Adriana R. Marques; Stephen E. Straus 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 2 views

Recent advances in our understanding of the replicative mechanism of HBV, and the development of potent nucleoside analogues as clinically effective inhibitors of the HIV reverse transcriptase or herpesvirus polymerases has opened a new era in the treatment of chronic HBV infection. Single agent the

New perspectives in the treatment of HBe

New perspectives in the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B

✍ Thomas Berg 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term

Randomized Controlled Trial of Quinacrin

Randomized Controlled Trial of Quinacrine for the Treatment of HBsAg-Positive Chronic Hepatitis

✍ Henry C. Bodenheimer Jr.; Fenton Schaffner; Salvatore Vernace; Shalom Z. Hirschm 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB 👁 1 views

Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)-positive chronic hepatitis, may lead to elimination of viral infection, we conducted

Treatment of chronic hepatitis C with co

Treatment of chronic hepatitis C with consensus interferon: A multicenter, randomized, controlled trial

✍ M J Tong; K R Reddy; W M Lee; P J Pockros; J C Hoefs; E B Keeffe; F B Hollinger; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 222 KB 👁 2 views

AND THE CONSENSUS INTERFERON STUDY GROUP 15 tion. Efficacy was assessed by normalization of serum alanine This multicenter, randomized, controlled, double-blind, transaminase (ALT) concentration and decrease in serum hepphase III study in 704 patients with chronic hepatitis C infecatitis C virus (HC

Treatment of chronic hepatitis C with in

Treatment of chronic hepatitis C with interferon alfa-n3: A multicenter, randomized, open-label trial

✍ D M Simon; S C Gordon; M M Kaplan; R S Koff; F Regenstein; G Everson; Y M Lee; F 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 217 KB 👁 2 views

We studied the antiviral effectiveness and safety of interferon alfa-n3, a natural alpha interferon which contains multiple interferon species, in the treatment of previously untreated patients with chronic hepatitis C. Seventy-seven patients were randomized to receive either 1.0, 2.5, 5.0, or 10.0

Randomized controlled trial of pegylated

Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6

✍ Khoa D. Lam; Huy N. Trinh; Son T. Do; Thuan T. Nguyen; Ruel T. Garcia; Tuan Nguy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 246 KB 👁 2 views

Hepatitis C virus (HCV) genotype is an important criteria in determining duration of therapy and predictor of sustained virologic response (SVR) to pegylated interferon (PEG IFN) and ribavirin (RBV) therapy. Optimal duration of therapy for patients with HCV genotype 6 is not known. We conducted a mu